Today: 21 December 2025
Subscribe
Browse Category

NYSE:ELV News 21 October 2025 - 12 December 2025

Elevance Health Stock (NYSE: ELV) News Today: Credit Ratings, ACA Subsidy Vote, and Analyst Forecasts on Dec. 12, 2025

Elevance Health Stock (NYSE: ELV) News Today: Credit Ratings, ACA Subsidy Vote, and Analyst Forecasts on Dec. 12, 2025

Elevance Health, Inc. (NYSE: ELV) is drawing fresh investor attention on December 12, 2025 as credit-rating updates and U.S. policy headlines collide with a stock that has recently rebounded sharply. The latest developments arrive at a sensitive moment for managed-care
12 December 2025
 ·  ·  ·  ·  · 
Elevance Health (ELV) Stock News Today: ACA Subsidy Deadline Looms, Fitch Affirms A- Rating, and Analysts See Modest Upside (Dec. 12, 2025)

Elevance Health (ELV) Stock News Today: ACA Subsidy Deadline Looms, Fitch Affirms A- Rating, and Analysts See Modest Upside (Dec. 12, 2025)

Elevance Health (NYSE: ELV) is stabilizing near the $360 level after a sharp rebound, while Washington’s failure to extend ACA subsidies raises new 2026 uncertainty. Here’s the latest news, credit outlook, analyst forecasts, and technical setup as of December 12,
12 December 2025
 ·  ·  ·  ·  · 
Elevance Health (ELV) Stock: December 2025 Outlook After Q3 Earnings Beat, Legal Headwinds and New Analyst Targets

Elevance Health (ELV) Stock: December 2025 Outlook After Q3 Earnings Beat, Legal Headwinds and New Analyst Targets

As of early December 3, 2025, Elevance Health, Inc. (NYSE: ELV) is trading around $331 per share, leaving the managed-care giant roughly 30% below its 52‑week high near $459, even after a strong third‑quarter earnings beat and renewed institutional buying.
3 December 2025
 ·  ·  ·  ·  · 
Elevance Health Stock Soars on Massive Q3 Earnings Beat – What It Means for Investors

Elevance Health Stock Soars on Massive Q3 Earnings Beat – What It Means for Investors

Earnings Beat Drives Stock Higher Elevance Health posted strong third-quarter 2025 results, significantly outperforming market expectations on both profit and revenue. Adjusted earnings came in at $6.03 per share, well above the ~$4.95 analysts predicted investing.com. Likewise, revenue for the
21 October 2025
 ·  ·  ·  ·  · 
Go toTop